Article
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Pharmacogenetics and genomics - 1 Sept 2017
Lloberas Nuria, Elens Laure, Llaudó Ines, Padullés Ariadna, van Gelder Teun, Hesselink Dennis A, Colom Helena, Andreu Franc, Torras Joan, Bestard Oriol, Cruzado Josep M, Gil-Vernet Salvador, van Schaik Ron, Grinyó Josep M
Abstract excerpt
INTRODUCTION: Tacrolimus (Tac) has a narrow therapeutic window and shows large between-patient pharmacokinetic variability. As a result, over-immunosuppression and under-immunosuppression are frequently encountered in daily clinical practice. Unraveling the impact of genetic polymorphisms on Tac pharmacokinetics may help to refine therapy. In this study, the associations of single-nucleotide polymorphisms (SNPs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
